ContraFect Reports Submission Of IND Application To FDA For Its Development Candidate CF-370
Portfolio Pulse from Benzinga Newsdesk
ContraFect has submitted an IND application to the FDA for its development candidate CF-370, an intravenous antibacterial agent for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia.
September 18, 2023 | 11:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ContraFect's submission of an IND application to the FDA for CF-370 could potentially lead to a new revenue stream if approved.
The submission of an IND application to the FDA is a significant step in the drug development process. If approved, CF-370 could provide a new treatment option for hospital-acquired and ventilator-associated bacterial pneumonia, potentially leading to increased revenues for ContraFect.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100